BFRG BULLFROG AI HOLDINGS

BullFrog AI Founder and CEO Vin Singh to Present Company Overview at Maxim Group’s Emerging Growth in AI Virtual Tech Conference Series

BullFrog AI Founder and CEO Vin Singh to Present Company Overview at Maxim Group’s Emerging Growth in AI Virtual Tech Conference Series

GAITHERSBURG, Md., Sept. 14, 2023 (GLOBE NEWSWIRE) -- (NASDAQ: BFRG; BFRGW) ("BullFrog AI" or the "Company"), a technology-enabled drug development company using artificial intelligence (AI) and machine learning to enable the successful development of pharmaceuticals and biologics, today announced that its founder and CEO Vin Singh will give a virtual presentation as part of Maxim Group’s 2023 Virtual Tech Conference Series, , scheduled to take place from September 26-27, 2023, and hosted on M-VEST. The presentation will include an overview of the company and its programs with a Q&A for investors in virtual attendance to follow.

Presentation Name: BullFrog AI Company Overview

Presenter: Vin Singh, Founder and CEO, BullFrog AI

Date/Time: September 26, 2023 10:30-11:00 a.m. EDT

The two-day event is limited to members of M-VEST. Listeners can sign up

About BullFrog AI

BullFrog AI is a technology-enabled drug development company that creates and analyzes networks of biological clinical and real-world data spanning from early discovery to late-stage clinical trials. Through its collaborations with leading research institutions, including Johns Hopkins University, BullFrog AI is at the forefront of AI-driven drug development using its proprietary bfLEAP™ artificial intelligence platform. BullFrog AI is deploying bfLEAP™ for use at several critical stages of development with the intention of streamlining data analytics in therapeutics development, decreasing the overall development costs by decreasing failure rates for new therapeutics.

For more information visit BullFrog AI at:

Website:

LinkedIn:

Safe Harbor Statement

This press release contains forward-looking statements. We base these forward-looking statements on our expectations and projections about future events, which we derive from the information currently available to us. Such forward-looking statements relate to future events or our future performance, including: our financial performance and projections; our growth in revenue and earnings; and our business prospects and opportunities. You can identify forward-looking statements by those that are not historical in nature, particularly those that use terminology such as "may," "should," "expects," "anticipates," "contemplates," "estimates," "believes," "plans," "projected," "predicts," "potential," or "hopes" or the negative of these or similar terms. In evaluating these forward-looking statements, you should consider various factors, including: our ability to change the direction of the Company; our ability to keep pace with new technology and changing market needs; and the competitive environment of our business. These and other factors may cause our actual results to differ materially from any forward-looking statement. Forward-looking statements are only predictions. The forward-looking events discussed in this press release and other statements made from time to time by us or our representatives, may not occur, and actual events and results may differ materially and are subject to risks, uncertainties, and assumptions about us. We are not obligated to publicly update or revise any forward-looking statement, whether as a result of uncertainties and assumptions, the forward-looking events discussed in this press release and other statements made from time to time by us or our representatives might not occur.

Contact:

Investors

Dave Gentry

RedChip Companies, Inc.



800-733-2447

Media



Eric Reiss



802-249-1136

Dave Schemelia



609-468-9325

SOURCE: BullFrog AI Holdings, Inc.



EN
14/09/2023

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on BULLFROG AI HOLDINGS

 PRESS RELEASE

BullFrog AI Expands Sales and Marketing Team to Accelerate Commercial ...

BullFrog AI Expands Sales and Marketing Team to Accelerate Commercial Adoption of Clinical Trial Optimization Solutions and bfPREP™ Module GAITHERSBURG, Md., Sept. 30, 2025 (GLOBE NEWSWIRE) --  (NASDAQ: BFRG; BFRGW) ("BullFrog AI" or the "Company"), a technology-enabled drug development company using artificial intelligence (“AI”) and machine learning to enable the successful development of pharmaceuticals and biologics, today announced the expansion of its internal sales organization to support accelerated commercialization of the Company’s clinical trial optimization offerings, includin...

 PRESS RELEASE

BullFrog AI and Sygnature Discovery Announce Official Sales Launch of ...

BullFrog AI and Sygnature Discovery Announce Official Sales Launch of BullFrog Data Networks™ to Global Biopharma Clients Sales launch marks pivotal commercial milestone, unlocking up to $30 million in potential revenue through 2028 GAITHERSBURG, Md., Sept. 25, 2025 (GLOBE NEWSWIRE) --  (NASDAQ: BFRG; BFRGW) ("BullFrog AI" or the "Company"), a technology-enabled drug development company using artificial intelligence (“AI”) and machine learning to enable the successful development of pharmaceuticals and biologics, today announced that its collaboration with Sygnature Discovery, a leading...

 PRESS RELEASE

BullFrog AI to Showcase AI-Powered Clinical Data Solutions in Xtalks W...

BullFrog AI to Showcase AI-Powered Clinical Data Solutions in Xtalks Webinar GAITHERSBURG, Md., Sept. 23, 2025 (GLOBE NEWSWIRE) --  (NASDAQ: BFRG; BFRGW) ("BullFrog AI" or the "Company"), a technology-enabled drug development company using artificial intelligence (“AI”) and machine learning to enable the successful development of pharmaceuticals and biologics, that its Director of AI, Machine Learning & Innovation, Juan Felipe Beltrán Lacouture, PhD, will present a hosted by Xtalks titled “Clinical Data Analysis with Agents: Reliable Automation with Human Oversight.” The webinar will tak...

 PRESS RELEASE

BullFrog AI’s bfPREP™ and bfLEAP® Platforms Deliver Real-World Impact ...

BullFrog AI’s bfPREP™ and bfLEAP® Platforms Deliver Real-World Impact in Eleison Pharmaceuticals Collaboration Joint oncology conference submission planned and follow-on contract discussion underway Validates BullFrog AI’s enterprise-grade platform strategy, combining automation and human-in-the-loop oversight for scalable, trustworthy analytics GAITHERSBURG, Md., Sept. 08, 2025 (GLOBE NEWSWIRE) --  (NASDAQ: BFRG; BFRGW) ("BullFrog AI" or the "Company"), a technology-enabled drug development company using artificial intelligence (“AI”) and machine learning to enable the successful ...

 PRESS RELEASE

BullFrog AI to Present at BTIG Annual Virtual Biotechnology Conference

BullFrog AI to Present at BTIG Annual Virtual Biotechnology Conference GAITHERSBURG, Md., July 28, 2025 (GLOBE NEWSWIRE) --  (NASDAQ: BFRG; BFRGW) ("BullFrog AI" or the "Company"), a technology-enabled drug development company using artificial intelligence ("AI") and machine learning to enable the successful development of pharmaceuticals and biologics, today announced that Vin Singh, CEO, will participate in a fireside chat and one-on-one meetings at BTIG’s Annual Virtual Biotechnology Conference, being held Tuesday, July 29 through Wednesday, July 30. Fireside Presentation De...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch